Anacor Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare Conference
May 02 2016 - 08:30AM
Business Wire
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that
the company’s management team will provide a company overview at
the Deutsche Bank 41st Annual Healthcare Conference on Thursday,
May 5, 2016 at 2:10 p.m. ET / 11:10 a.m. PT in Boston,
Massachusetts. The event will be webcast live and may be accessed
under “Events and Presentations” on the Investors page of Anacor’s
website at www.anacor.com. A replay will also be available for
three months following the presentation.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering,
developing and commercializing novel small-molecule therapeutics
derived from its boron chemistry platform. Anacor’s first approved
product, KERYDIN® (tavaborole) topical solution, 5%, is an
oxaborole antifungal approved by the U.S. Food and Drug
Administration in July 2014 for the topical treatment of
onychomycosis of the toenails. In July 2014, Anacor entered into an
exclusive agreement with Sandoz Inc., a Novartis company, pursuant
to which PharmaDerm, the branded dermatology division of Sandoz,
distributes and commercializes KERYDIN in the United States. In
September 2014, PharmaDerm launched KERYDIN. Anacor’s lead product
development candidate is crisaborole topical ointment, 2%, a novel
non-steroidal topical anti-inflammatory PDE-4 inhibitor in
development for the potential treatment of mild-to-moderate atopic
dermatitis and psoriasis. Beyond KERYDIN and crisaborole, Anacor
has discovered three investigational compounds that it has
out-licensed for further development. Anacor also has a pipeline of
other internally discovered topical and systemic boron-based
compounds in early stages of research and development. For more
information, visit www.anacor.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160502005417/en/
Anacor Pharmaceuticals, Inc.DeDe Sheel, 650-543-7575Senior
Director, Investor Relations and Corporate Communications
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)
Historical Stock Chart
From Mar 2023 to Mar 2024